Correlation Between Changes in Liver Stiffness and Preeclampsia as Shown by Fibroscan
Compare the Fibroscan results of preeclamptic women to normal controls and to find out if the changes are reversible after labor.
Materials and Methods
調査の概要
状態
条件
詳細な説明
The purpose of the study is to compare the Fibroscan results of preeclamptic women to normal controls and to find out if the changes are reversible after labor.
Materials and Methods This prospective observational case-control study will include 50 women admitted to the fetal-maternal Unit at 24 - 41 weeks gestation and diagnosed with mild/severe preeclampsia. Preeclampsia is diagnosed as a new onset of hypertension over 140/90, at least two measurements at least four hours apart, and proteinuria (≥+1 in dipstick or >300 mg/24 hr) after 20 weeks of gestation in a previously normotensive woman.
A control group will consist 100 normotensive women with normal pregnancy outcomes who were admitted to our fetal-maternal unit during the same period. Demographic, clinical, laboratory and sonographic data for the women participating will be collected from their chart. All patients diagnosed with preeclampsia will undergo the following workup: sign and symptoms evaluation, blood pressure follow up, 24-hour protein excretion in grams per day, complete blood count, hepatic function test: AST, ALT and coagulation study, HBA1C, coagulation function test and fibrotest. The Fibroscan test will be performed by a trained hepatologist, who was blind to the women diagnosis. The fibroscan test will be done during the admission after the diagnosis of preeclampsia, after delivery and 6 weeks post-partum.
Commonly used cutoffs are >7 kPa for significant fibrosis. Statistical analysis will be performed with SPSS using Mann Whitney test. Continuous variables will be analyzed using the student's T test and categorical variables were analyzed using 2. Statistical significance was set at a P value of < 0.05. The local institutional review board approved this study.
研究の種類
入学 (予想される)
連絡先と場所
研究場所
-
-
-
Nahariya、イスラエル
- 募集
- Galil Medical Center
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- Fetal-maternal Unit at 24 - 41 weeks gestation and diagnosed with mild/severe preeclampsia
Exclusion Criteria:
- Age less then 18
- Fetal-maternal less then 24 weeks
研究計画
研究はどのように設計されていますか?
デザインの詳細
コホートと介入
グループ/コホート |
---|
Control group
A control group will consist 100 normotensive women with normal pregnancy outcomes who were admitted to our fetal-maternal unit during the same period
|
Preeclampsia group
All patients diagnosed with preeclampsia will undergo the fibroscan test.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Comparing the Fibroscan results of preeclamptic women to normal controls and to find out if the changes are reversible after labor. Fibrotic tissue differs from healthy tissue in the way it responds to excitation
時間枠:2 years
|
Transient elastography is performed using transducer-induced vibrations at low frequency (50 Hz) and amplitudes.
The transmitted shear waves propagate through the liver parenchyma.
Pulse-echo ultrasound acquisition is used to follow the propagation of the shear wave and to measure its average speed.
Results are expressed in kPa and can range from 2.5 to 75 kPa.
Commonly used cutoffs in clinical settings are >7 kPa for significant fibrosis and >11 to 14 kPa for cirrhosis and CAP>270 db/m2 for significant steatosis.
|
2 years
|
協力者と研究者
捜査官
- 主任研究者:Maya Wolf, MD、Western Galilee Medical Center
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (予想される)
研究の完了 (予想される)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
子癇前症の臨床試験
-
Amsterdam UMC, location VUmcRadboud University Medical Center; Maastricht University Medical Center; GGZ inGeest; Neurocare; M... と他の協力者募集